G
GlySens
Privately held corporation that is committed to developing a long term glucose sensor system to continuously
About GlySens
GlySens Incorporated is at the forefront of diabetes care innovation, specializing in the development of an implantable glucose sensor system. The company's primary product, the Eclipse 3 System, is designed to provide continuous glucose monitoring for individuals with diabetes, aiming to improve their quality of life and health outcomes. GlySens operates in the medical device market, targeting patients with diabetes, healthcare providers, and potentially insurance companies. The business model revolves around the development, clinical evaluation, and eventual commercialization of its glucose monitoring system. Revenue will be generated through the sale of the Eclipse 3 System and potentially through partnerships with healthcare institutions and insurance providers. Currently, the system is under clinical evaluation and not yet available for commercial distribution.
Source: Dealroom company dataAt a glance
- Founded
- 1998
- Headquarters
- San Diego, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GlySens on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GlySens on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.